Market Intelligence, Clinical Progress, and High-Purity Reagents for Medullary Thyroid Carcinoma and RET-Co-Receptor Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GFRA4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GFRA4 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View GFRA4 Products |
| Gene Delivery | GFRA4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View GFRA4 Products |
| Benchmark Ab | Anti-GFRA4 Recombinant Antibody Recombinant positive control derived from public benchmark sequences. |
View GFRA4 Products |
| Validator | GFRA4 siRNA Set For knockdown verification and specificity validation. |
View GFRA4 Products |
| Related Target A | RET Receptor tyrosine kinase that complexes with GFRA4 to mediate Persephin signaling. |
View RET Products |
| Related Target B | GFRAL GDNF family receptor alpha-like; critical homolog for off-target and selectivity counter-screening. |
View GFRAL Products |
| Related Target C | GFRA1 GDNF family receptor alpha 1; key homolog for off-target profiling. |
View GFRA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog Off-Target Cross-Reactivity (GFRA1/2/3/GFRAL) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis for comparative SPR/ELISA. |
| Conformational Integrity for Cell-Based Assays | Lentiviral vectors for stable cell line generation, preserving native GPI-anchored conformation. |
| Lack of Validated Reference Tools | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positive Knockdown Signals | Sequence-verified siRNA pool included for target specificity validation. |
Live GFRA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GFRA4 (GDNF family receptor alpha 4) is an emerging frontier in oncology and endocrinology, particularly for medullary thyroid carcinoma (MTC) and RET-driven malignancies. As a GPI-anchored co-receptor that binds Persephin (PSN) to activate the RET receptor tyrosine kinase, GFRA4 exhibits highly restricted expression in normal tissues but is significantly upregulated in specific neuroendocrine tumors. The race for GFRA4 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs). As first-generation RET inhibitors face resistance mutations, targeting the extracellular co-receptor GFRA4 offers a promising alternative or combination strategy to bypass intracellular resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech Startups / Academic Consortia | Medullary Thyroid Carcinoma (MTC) | Internalization Assay (Requires high-purity, native glycosylated ECD-Fc protein) |
| Bispecific Antibodies (e.g., GFRA4 x CD3) | Oncology-focused Biopharma | RET-mutant Solid Tumors | Dual-binding kinetics validation (Requires high-purity monomeric GFRA4 and CD3 proteins) |
| Small Molecule / Peptide Antagonists | Targeted Therapy Specialists | Neuroendocrine Tumors, RET Resistance | Selectivity Assay (Requires complete GFRA subfamily counter-screening panel) |